Immunotherapy drug keytruda tested against aggressive brain cancer
NCT ID NCT02852655
First seen Mar 31, 2026 · Last updated Jun 21, 2026 · Updated 9 times
Summary
This early-stage trial tests the immunotherapy drug pembrolizumab (Keytruda) in 60 adults with recurrent glioblastoma, a fast-growing brain cancer. The study aims to see how the drug affects immune cells in the tumor and whether it is safe. Participants receive pembrolizumab before and after surgery to remove their tumor.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BRAIN CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Dana Farber Cancer Institute
Boston, Massachusetts, 02115, United States
-
Huntsman Cancer Institute
Salt Lake City, Utah, 84112, United States
-
Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
-
Memorial Sloan-Kettering Cancer
New York, New York, 10065, United States
-
UT, MD Anderson Cancer Center
Houston, Texas, 77030, United States
-
University of California, Los Angeles
Los Angeles, California, 90095, United States
-
University of California, San Francisco
San Francisco, California, 94143-0372, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Pembrolizumab (Keytruda), an immunotherapy drug that helps the immune system attack cancer cells
What this could lead to
If successful, this could point toward a new treatment option for recurrent glioblastoma, a difficult-to-treat brain cancer.
What could go wrong
This is an early Phase 1 trial with only 60 participants, so results are preliminary. The drug may not improve survival and could cause serious side effects.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.